{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T19:55:20Z","timestamp":1776023720153,"version":"3.50.1"},"reference-count":58,"publisher":"CSIRO Publishing","issue":"5","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":2176,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,13]]},"abstract":"<jats:p>Efforts to develop vaccines against Neisseria gonorrhoeae have become increasingly important, given the rising threat of gonococcal antimicrobial resistance (AMR). Recent data suggest vaccines for gonorrhoea are biologically feasible; in particular, epidemiological evidence shows that vaccines against a closely related pathogen, serogroup B Neisseria meningitidis outer membrane vesicle (OMV) vaccines, may reduce gonorrhoea incidence. Vaccine candidates using several approaches are currently in preclinical development, including meningococcal and gonococcal OMV vaccines, a lipooligosaccharide epitope and purified protein subunit vaccines. The Global STI Vaccine Roadmap provides action steps to build on this technical momentum and advance gonococcal vaccine development. Better quantifying the magnitude of gonorrhoea-associated disease burden, for outcomes like infertility, and modelling the predicted role of gonococcal vaccines in addressing AMR will be essential for building a full public health value proposition, which can justify investment and help with decision making about future vaccine policy and programs. Efforts are underway to gain consensus on gonorrhoea vaccine target populations, implementation strategies and other preferred product characteristics that would make these vaccines suitable for use in low- and middle-income, as well as high-income, contexts. Addressing these epidemiological, programmatic and policy considerations in parallel to advancing research and development, including direct assessment of the ability of meningococcal B OMV vaccines to prevent gonorrhoea, can help bring about the development of viable gonococcal vaccines.<\/jats:p>","DOI":"10.1071\/sh19060","type":"journal-article","created":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T19:19:02Z","timestamp":1567451942000},"page":"426-432","source":"Crossref","is-referenced-by-count":40,"title":["Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap"],"prefix":"10.1071","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4398-3441","authenticated-orcid":true,"given":"Sami L.","family":"Gottlieb","sequence":"first","affiliation":[{"name":"ADepartment of Reproductive Health and Research, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland."},{"name":"FCorresponding author. Email: gottliebs@who.int"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann E.","family":"Jerse","sequence":"additional","affiliation":[{"name":"BUniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinead","family":"Delany-Moretlwe","sequence":"additional","affiliation":[{"name":"CWits RHI, University of the Witwatersrand, 22 Esselen Street, 2001 Johannesburg, South Africa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Deal","sequence":"additional","affiliation":[{"name":"DNational Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Bethesda, MD 20892, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgitte K.","family":"Giersing","sequence":"additional","affiliation":[{"name":"EDepartment of Immunizations, Vaccines, and Biologicals, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"2025102615523495000_R1","unstructured":"World Health Organization. Report on global sexually transmitted infection surveillance, 2018. 2018. Available online at: https:\/\/www.who.int\/reproductivehealth\/publications\/stis-surveillance-2018\/en\/ [verified 1 July 2019]."},{"key":"2025102615523495000_R2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S0968-8080(12)40653-X","article-title":"The threat of untreatable gonorrhoea: implications and consequences for reproductive and sexual morbidity.","volume":"20","author":"Ndowa","year":"2012","journal-title":"Reprod Health Matters"},{"key":"2025102615523495000_R3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205863","article-title":"Adult gonorrhea, chlamydia and syphilis prevalence, incidence, treatment and syndromic case reporting in South Africa: estimates using the Spectrum-STI model, 1990\u20132017.","volume":"13","author":"Kularatne","year":"2018","journal-title":"PLoS One"},{"key":"2025102615523495000_R4","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/S0140-6736(97)02190-9","article-title":"Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1.","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"key":"2025102615523495000_R5","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1097\/01.aids.0000390704.35642.47","article-title":"Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning?","volume":"24","author":"Hayes","year":"2010","journal-title":"AIDS"},{"key":"2025102615523495000_R6","unstructured":"World Health Organization. The gonococcal antimicrobial surveillance programme (GASP). 2019. Available online at: https:\/\/www.who.int\/reproductivehealth\/topics\/rtis\/gasp_network\/en\/ [verified 1 July 2019]."},{"key":"2025102615523495000_R7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002344","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action.","volume":"14","author":"Wi","year":"2017","journal-title":"PLoS Med"},{"key":"2025102615523495000_R8","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","article-title":"Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018.","volume":"23","author":"Eyre","year":"2018","journal-title":"Euro Surveill"},{"key":"2025102615523495000_R9","unstructured":"World Health Organization (WHO). WHO publishes list of bacteria for which new antibiotics are urgently needed. [News release] 2017. Available online at: http:\/\/www.who.int\/mediacentre\/news\/releases\/2017\/bacteria-antibiotics-needed\/en\/ [verified 1 July 2019]."},{"key":"2025102615523495000_R10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jama.2012.205107","article-title":"Cephalosporin-resistant gonorrhea in North America.","volume":"309","author":"Kirkcaldy","year":"2013","journal-title":"JAMA"},{"key":"2025102615523495000_R11","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.vaccine.2013.08.067","article-title":"Vaccines against gonorrhea: current status and future challenges.","volume":"32","author":"Jerse","year":"2014","journal-title":"Vaccine"},{"key":"2025102615523495000_R12","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study.","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"key":"2025102615523495000_R13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/vaccines7010005","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study.","volume":"7","author":"Paynter","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"2025102615523495000_R14","doi-asserted-by":"publisher","first-page":"S734","DOI":"10.1093\/ofid\/ofx180.002","article-title":"Possible impact of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhea incidence rates in one region of Quebec, Canada.","volume":"4","author":"Longtin","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2025102615523495000_R15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3201\/eid2206.151093","article-title":"Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection, Norway.","volume":"22","author":"Whelan","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2025102615523495000_R16","unstructured":"Wellcome Trust and BCG. Vaccines to tackle drug resistant infections. An evaluation of R&D opportunities. Executive summary. 2018. Available online at: https:\/\/vaccinesforamr.org\/read-the-report\/ [verified 1 July 2019]."},{"key":"2025102615523495000_R17","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.vaccine.2014.01.053","article-title":"Vaccines against sexually transmitted infections: the way forward.","volume":"32","author":"Broutet","year":"2014","journal-title":"Vaccine"},{"key":"2025102615523495000_R18","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.vaccine.2016.03.111","article-title":"The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps.","volume":"34","author":"Gottlieb","year":"2016","journal-title":"Vaccine"},{"key":"2025102615523495000_R19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jtbi.2016.09.004","article-title":"In-silico hierarchical approach for the identification of potential universal vaccine candidates (PUVCs) from Neisseria gonorrhoeae.","volume":"410","author":"Jain","year":"2016","journal-title":"J Theor Biol"},{"key":"2025102615523495000_R20","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1074\/mcp.M116.058800","article-title":"Proteomics-driven antigen discovery for development of vaccines against gonorrhea.","volume":"15","author":"Zielke","year":"2016","journal-title":"Mol Cell Proteomics"},{"key":"2025102615523495000_R21","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.3389\/fmicb.2018.02971","article-title":"PubMLST for antigen allele mining to inform development of gonorrhea protein-based vaccines.","volume":"9","author":"Baarda","year":"2018","journal-title":"Front Microbiol"},{"key":"2025102615523495000_R22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae.","author":"Semchenko","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025102615523495000_R23","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1146\/annurev-micro-090816-093530","article-title":"Neisseria gonorrhoeae: drug resistance, mouse models, and vaccine development.","volume":"71","author":"Rice","year":"2017","journal-title":"Annu Rev Microbiol"},{"key":"2025102615523495000_R24"},{"key":"2025102615523495000_R25"},{"key":"2025102615523495000_R26","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/mi.2017.11","article-title":"Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model.","volume":"10","author":"Liu","year":"2017","journal-title":"Mucosal Immunol"},{"key":"2025102615523495000_R27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0140-6736(85)90594-X","article-title":"Worldwide patterns of infertility: is Africa different?","volume":"326","author":"Cates","year":"1985","journal-title":"Lancet"},{"key":"2025102615523495000_R28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018630","article-title":"Performance of syndromic management for the detection and treatment of genital Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis among women attending antenatal, well woman and sexual health clinics in Papua New Guinea: a cross-sectional study.","volume":"7","author":"Vallely","year":"2017","journal-title":"BMJ Open"},{"key":"2025102615523495000_R29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002511","article-title":"Prevalence of sexually transmitted infections and bacterial vaginosis among women in Sub-Saharan Africa: an individual participant data meta-analysis of 18 HIV prevention studies.","volume":"15","author":"Torrone","year":"2018","journal-title":"PLoS Med"},{"key":"2025102615523495000_R30","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1136\/sextrans-2016-053073","article-title":"Advancing point of care diagnostics for the control and prevention of STIs: the way forward.","volume":"93","author":"Toskin","year":"2017","journal-title":"Sex Transm Infect"},{"key":"2025102615523495000_R31","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1016\/j.vaccine.2015.07.015","article-title":"The potential impact of vaccination on the prevalence of gonorrhea.","volume":"33","author":"Craig","year":"2015","journal-title":"Vaccine"},{"key":"2025102615523495000_R32","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.4161\/hv.36221","article-title":"Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model.","volume":"10","author":"R\u00e9gnier","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2025102615523495000_R33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005611","article-title":"Antibiotic-resistant Neisseria gonorrhoeae spread faster with more treatment, not more sexual partners.","volume":"12","author":"Fingerhuth","year":"2016","journal-title":"PLoS Pathog"},{"key":"2025102615523495000_R34","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/infdis\/jit094","article-title":"Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection.","volume":"207","author":"Geisler","year":"2013","journal-title":"J Infect Dis"},{"key":"2025102615523495000_R35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fmicb.2011.00123","article-title":"Experimental gonococcal infection in male volunteers: cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkc.","volume":"2","author":"Hobbs","year":"2011","journal-title":"Front Microbiol"},{"key":"2025102615523495000_R36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/sextrans-2014-051731","article-title":"Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant Neisseria gonorrhoeae strains?","volume":"91","author":"Lewis","year":"2015","journal-title":"Sex Transm Infect"},{"key":"2025102615523495000_R37","unstructured":"World Health Organization (WHO). WHO preferred product characteristics (PPCs). 2019. Available online at: http:\/\/www.who.int\/immunization\/research\/ppc-tpp\/preferred_product_characteristics\/en\/ [verified 1 July 2019]."},{"key":"2025102615523495000_R38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.10.084","article-title":"Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.","author":"Gottlieb","year":"2017","journal-title":"Vaccine"},{"key":"2025102615523495000_R39","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1071\/SH15227","article-title":"Prevalence and risk factors of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and other sexually transmissible infections among women attending antenatal clinics in three provinces in Papua New Guinea: a cross-sectional survey.","volume":"13","author":"Vallely","year":"2016","journal-title":"Sex Health"},{"key":"2025102615523495000_R40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/OLQ.0b013e31827c5a71","article-title":"Prevalence of Neisseria gonorrhoeae among persons 14 to 39 years of age, United States, 1999 to 2008.","volume":"40","author":"Torrone","year":"2013","journal-title":"Sex Transm Dis"},{"key":"2025102615523495000_R41","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/OLQ.0000000000000786","article-title":"Self-reported chlamydia and gonorrhea testing and diagnosis among men who have sex with men \u2013 20 US cities, 2011 and 2014.","volume":"45","author":"Hoots","year":"2018","journal-title":"Sex Transm Dis"},{"key":"2025102615523495000_R42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/OLQ.0b013e318244a923","article-title":"Low rates of hepatitis screening and vaccination of HIV-infected MSM in HIV clinics.","volume":"39","author":"Hoover","year":"2012","journal-title":"Sex Transm Dis"},{"key":"2025102615523495000_R43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nm.4465","article-title":"The role of vaccines in preventing bacterial antimicrobial resistance.","volume":"24","author":"Jansen","year":"2018","journal-title":"Nat Med"},{"key":"2025102615523495000_R44","unstructured":"Royal Society. The value of vaccines in the avoidance of antimicrobial resistance. Centre on Global Health Security meeting summary. 2017. Available online at: https:\/\/www.chathamhouse.org\/sites\/default\/files\/events\/2017-03-30-amr-vaccines-meeting-summary.pdf [verified 1 July 2019]."},{"key":"2025102615523495000_R45","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.vaccine.2013.08.032","article-title":"Current barriers, challenges and opportunities for the development of effective STI vaccines: point of view of vaccine producers, biotech companies and funding agencies.","volume":"32","author":"Dodet","year":"2014","journal-title":"Vaccine"},{"key":"2025102615523495000_R46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.bbrc.2012.12.132","article-title":"Recombinant truncated AniA of pathogenic Neisseria elicits a non-native immune response and functional blocking antibodies.","volume":"431","author":"Shewell","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"2025102615523495000_R47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jinf.2018.06.001","article-title":"Gonococcal MtrE and its surface-expressed Loop 2 are immunogenic and elicit bactericidal antibodies.","volume":"77","author":"Wang","year":"2018","journal-title":"J Infect"},{"key":"2025102615523495000_R48","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fimmu.2019.00137","article-title":"The Neisseria gonorrhoeae methionine sulfoxide reductase (msra\/b) is a surface exposed, immunogenic, vaccine candidate.","volume":"10","author":"Jen","year":"2019","journal-title":"Front Immunol"},{"key":"2025102615523495000_R49","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1086\/315801","article-title":"Intranasal immunization with gonococcal outer membrane preparations reduces the duration of vaginal colonization of mice by Neisseria gonorrhoeae.","volume":"182","author":"Plante","year":"2000","journal-title":"J Infect Dis"},{"key":"2025102615523495000_R50"},{"key":"2025102615523495000_R51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003559","article-title":"Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection.","volume":"9","author":"Gulati","year":"2013","journal-title":"PLoS Pathog"},{"key":"2025102615523495000_R52","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/infdis\/174.6.1238","article-title":"Experimental immunization with a monoclonal antiidiotope antibody that mimics the Neisseria gonorrhoeae lipooligosaccharide epitope 2C7.","volume":"174","author":"Gulati","year":"1996","journal-title":"J Infect Dis"},{"key":"2025102615523495000_R53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182555","article-title":"Refinement of immunizing antigens to produce functional blocking antibodies against the AniA nitrite reductase of Neisseria gonorrhoeae.","volume":"12","author":"Shewell","year":"2017","journal-title":"PLoS One"},{"key":"2025102615523495000_R54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fimmu.2019.00137","article-title":"The Neisseria gonorrhoeae methionine sulfoxide reductase (MsrA\/B) is a surface exposed, immunogenic, vaccine candidate.","volume":"10","author":"Jen","year":"2019","journal-title":"Front Immunol"},{"key":"2025102615523495000_R55","doi-asserted-by":"publisher","first-page":"7247","DOI":"10.1016\/j.vaccine.2007.07.038","article-title":"Gonococcal transferrin binding protein chimeras induce bactericidal and growth inhibitory antibodies in mice.","volume":"25","author":"Price","year":"2007","journal-title":"Vaccine"},{"key":"2025102615523495000_R56","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fmicb.2011.00124","article-title":"Vaccines for gonorrhea: can we rise to the challenge?","volume":"2","author":"Zhu","year":"2011","journal-title":"Front Microbiol"},{"key":"2025102615523495000_R57","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/2211-5463.12267","article-title":"Structure-based design of ferritin nanoparticle immunogens displaying antigenic loops of Neisseria gonorrhoeae.","volume":"7","author":"Wang","year":"2017","journal-title":"FEBS Open Bio"},{"key":"2025102615523495000_R58","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/vaccines6030060","article-title":"Novel whole-cell inactivated Neisseria gonorrhoeae microparticles as vaccine formulation in microneedle-based transdermal immunization.","volume":"6","author":"Gala","year":"2018","journal-title":"Vaccines (Basel)"}],"container-title":["Sexual Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/16\/5\/426\/799259\/sh19060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/16\/5\/426\/799259\/sh19060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:52:40Z","timestamp":1761508360000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/sh\/article\/16\/5\/426\/101985\/Advancing-vaccine-development-for-gonorrhoea-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9,13]]}},"URL":"https:\/\/doi.org\/10.1071\/sh19060","relation":{},"ISSN":["1448-5028","1449-8987"],"issn-type":[{"value":"1448-5028","type":"print"},{"value":"1449-8987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]}}}